Re: Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
Debra A
DA
Goldstein
Howard H
HH
Tessler
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001932:Brain Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005451:Fluorescein Angiography; D006801:Humans; D007278:Injections, Spinal; D008223:Lymphoma / Q000188:drug therapy*; D008353:Mannitol / Q000008:administration & dosage / Q000009:adverse effects*; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects*; D010857:Pigment Epithelium of Eye / Q000187:drug effects / Q000473:pathology; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis
D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine; D008353:Mannitol; D005047:Etoposide; D003520:Cyclophosphamide; D008727:Methotrexate